Oculis Holding AG (OCS) Net Income towards Common Stockholders (2022 - 2026)

Oculis Holding AG's (OCS) quarterly Net Income towards Common Stockholders came in at -$625.73 in Q1 2026, up 18.47% year-on-year from -$528.19 in Q1 2025, and down 19.08% quarter-over-quarter from -$525.49 in Q4 2025.

Oculis Holding AG (OCS) Net Income towards Common Stockholders (2022 - 2026) Analysis & Trends

Oculis Holding AG's Net Income towards Common Stockholders history runs 5 years deep, the most recent figure standing at -$625.73 for Q1 2026.

  • On a quarterly basis, Net Income towards Common Stockholders rose 18.47% year-over-year to -$625.73 in Q1 2026; TTM through Mar 2026 was -$2143.1, a 19.13% increase from a year earlier, with the FY2025 full-year figure at -$2279.6, up 5.4% from the prior year.
  • Net Income towards Common Stockholders retreated to -$625.73 in Q1 2026 per OCS's latest filing, from -$525.49 in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at -$383.3 in Q4 2023 and bottomed at -$3859.8 in Q1 2023.
  • The 5-year median for Net Income towards Common Stockholders is -$577.91 (2025), against an average of -$1248.6.
  • Across the five-year window, Net Income towards Common Stockholders surged 88.82% in 2023 and slumped 99.54% in 2024, its largest moves.
  • Year by year, Net Income towards Common Stockholders stood at -$2709.2 in 2022, then soared by 85.85% to -$383.3 in 2023, then slumped by 99.54% to -$764.82 in 2024, then soared by 31.29% to -$525.49 in 2025, then retreated by 19.08% to -$625.73 in 2026.
  • Per Business Quant, the three latest OCS Net Income towards Common Stockholders figures stand at -$625.73 (Q1 2026), -$525.49 (Q4 2025), and -$400.04 (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn - -625.73
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -14.46 Mn
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn 227.36 Mn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn 1.03 Bn
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn 727.20 Mn
7 Belite Bio 61.40 Bn 61.40 Bn - -0.68
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn 366.00 Mn
9 Revolution Medicines 37.37 Bn 37.37 Bn - -453.82 Mn
10 Alnylam Pharmaceuticals 36.08 Bn 33.07 Bn 959.66 Mn 205.99 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -625.73
Dec 31, 2025 -525.49
Sep 30, 2025 -400.04
Jun 30, 2025 -591.87
Mar 31, 2025 -767.45
Dec 31, 2024 -764.82
Sep 30, 2024 -554.02
Jun 30, 2024 -563.95
Mar 31, 2024 -504.10
Dec 31, 2023 -383.30
Sep 30, 2023 -543.43
Jun 30, 2023 -422.63
Mar 31, 2023 -3,859.75
Dec 31, 2022 -2,709.24
Sep 30, 2022 -2,982.12
Jun 30, 2022 -3,779.39